Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM

June 17, 2013 by Brian Johnson

Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-invasive, wireless continuous glucose monitor.

Diabetes: Echo Therapeutics sends pre-submission package to FDA for Symphony needle-free CGM

Philadelphia-based Echo Therapeutics (NSDQ:ECTE) said it's taken another step toward obtaining FDA approval for its non-invasive, wireless continuous glucose monitoring system.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp